Relmada Therapeutics with ticker code (RLMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 75 and 38 calculating the mean target price we have 62.83. With the stocks previous close at 32.87 this would imply there is a potential upside of 91.1%. The 50 day MA is 34.12 while the 200 day moving average is 38.03. The market capitalisation for the company is $534m. Find out more information at: http://www.relmada.com
The potential market cap would be $1,021m based on the market concensus.
Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics was founded in 2004 and is headquartered in New York, New York.
